Abstract
Female genital tract graft-versus-host disease (GVHD) is an under-recognized complication of allogeneic stem cell transplantation impacting on quality of life. We describe a prospective surveillance programme for female genital GVHD to better characterize incidence, risk factors and clinical features and the impact of a structured intervention policy. A retrospective audit was conducted on the medical records of all female transplant recipients surviving at least 6 months at a single centre over a 5-year period. Patients commenced topical vaginal oestrogen early post transplant with hormone replacement as appropriate for age, prior menopausal status and co-morbidities. A genital tract management programme included regular gynaecological review and self-maintenance of vaginal capacity by dilator or intercourse. The incidence of genital GVHD was 35% (95% confidence interval (CI) (25, 50%)) at 1 year and 49% (95% CI (36, 63%)) at 2 years. Topical therapy was effective in most cases; no patient required surgical intervention to divide vaginal adhesions. The main risk factor was stem cell source with peripheral blood progenitor cells posing a higher risk than marrow (hazard ratio=3.07 (1.22, 7.73), P=0.017). Extensive GVHD in other organs was a common association. We conclude that female genital GVHD is common, and early detection and commencement of topical immunosuppression with dilator use appears to be highly effective at preventing progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Spinelli S, Chiodi S, Costantini S, Van Lint MT, Raiola AM, Ravera GB et al. Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation. Haematologica 2003; 88: 1163–1168.
Yanai N, Shufaro Y, Or R, Meirow D . Vaginal outflow tract obstruction by graft-versus-host reaction. Bone Marrow Transplant 1999; 24: 811–812.
DeLord C, Treleaven J, Shepherd J, Saso R, Powles RL . Vaginal stenosis following allogeneic bone marrow transplantation for acute myeloid leukaemia. Bone Marrow Transplant 1999; 23: 523–525.
Couriel D, Carpenter PA, Cutler C, Bolanos-Meade J, Treister NS, Gea-Banacloche J et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006; 12: 375–396.
Ruutu T, Volin L, Parkkali T, Juvonen E, Elonen E . Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood 2000; 96: 2391–2398.
Lobashevsky AL, Senkbeil RW, Townsend JE, Mink CA, Thomas JM . Quantitative analysis of chimerism using a short tandem repeat method on a fluorescent automated DNA sequencer. Clin Lab Haematol 2006; 28: 40–49.
Armitage JO . Bone marrow transplantation. N Engl J Med 1994; 330: 827–838.
Lee SJ, Vogelsang G, Flowers ME . Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215–233.
Schmitz N, Beksac M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E et al. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica 2005; 90: 643–648.
Flowers ME, Parker PM, Johnston LJ, Matos AV, Storer B, Bensinger WI et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002; 100: 415–419.
Spiryda LB, Laufer MR, Soiffer RJ, Antin JA . Graft-versus-host disease of the vulva and/or vagina: diagnosis and treatment. Biol Blood Marrow Transplant 2003; 9: 760–765.
Acknowledgements
We acknowledge the expert patient care provided by the staff at the Menopause Clinic, Royal Women's Hospital, Melbourne.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zantomio, D., Grigg, A., MacGregor, L. et al. Female genital tract graft-versus-host disease: incidence, risk factors and recommendations for management. Bone Marrow Transplant 38, 567–572 (2006). https://doi.org/10.1038/sj.bmt.1705487
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705487
Keywords
This article is cited by
-
Graft-versus-host disease in the female genital tract: a prospective cohort study
Archives of Gynecology and Obstetrics (2022)
-
Management and long-term consequences of genital graft versus host disease following hematopoietic stem cell transplantation
Bone Marrow Transplantation (2020)
-
The management of gynecological complications in long-term survivors after allogeneic hematopoietic cell transplantation—a single-center real-life experience
Annals of Hematology (2020)
-
Long-Term Follow-Up of Sexual Dysfunction in Women Following Allogeneic Hematopoietic Stem Cell Transplantation
Archives of Sexual Behavior (2019)
-
Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study
Bone Marrow Transplantation (2018)